pifithrin has been researched along with Cockayne Syndrome in 1 studies
pifithrin: a tetrahydrobenzothiazol; inhibitor of P53 that protects mice from the side effects of cancer therapy; structure in first source
Cockayne Syndrome: A syndrome characterized by multiple system abnormalities including DWARFISM; PHOTOSENSITIVITY DISORDERS; PREMATURE AGING; and HEARING LOSS. It is caused by mutations of a number of autosomal recessive genes encoding proteins that involve transcriptional-coupled DNA REPAIR processes. Cockayne syndrome is classified by the severity and age of onset. Type I (classical; CSA) is early childhood onset in the second year of life; type II (congenital; CSB) is early onset at birth with severe symptoms; type III (xeroderma pigmentosum; XP) is late childhood onset with mild symptoms.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Proietti De Santis, L | 1 |
| Balajee, AS | 1 |
| Lorenti Garcia, C | 1 |
| Pepe, G | 1 |
| Worboys, AM | 1 |
| Palitti, F | 1 |
1 other study available for pifithrin and Cockayne Syndrome
| Article | Year |
|---|---|
Inhibition of p53, p21 and Bax by pifithrin-alpha does not affect UV induced apoptotic response in CS-B cells.
Topics: Apoptosis; bcl-2-Associated X Protein; Benzothiazoles; Cells, Cultured; Cockayne Syndrome; Electroph | 2003 |